Cat. No.: HY-13002

Torin 2

21 Cited Publications

Avis client

Based on 21 publication(s) in Google Scholar

Torin 2 is an mTOR inhibitor with EC₅₀ of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC₅₀: 200 nM). Torin 2 also inhibits DNA-PK with an IC₅₀ of 0.5 nM in the cell free assay. Torin 2 can suppress both mTORC1 and mTORC2.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.65%
CAS No.: 1223001-51-1
Formule: C₂₄H₁₅F₃N₄O
Masse moléculaire:432.40

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Torin 2 Chemical Structure

CAS No.: 1223001-51-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (21)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]^[4]

mTOR

2.81 nM (IC₅₀)

mTOR

0.25 nM (EC₅₀, Cell Assay)

mTORC1

mTORC2

DNA-PK

0.5 nM (IC₅₀)

p110γ

5.67 nM (IC₅₀)

PI3K-C2β

24.5 nM (IC₅₀)

PI3K-C2α

28.1 nM (IC₅₀)

hVps34

8.58 nM (IC₅₀)

PI3K

200 nM (EC₅₀, Cell Assay)

ΡΙ4Κβ

18.3 nM (IC₅₀)

Autophagy

Voir tous les produits spécifiques à Isoform mTOR :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	GI₅₀	32.19 nM Compound: Torin2	Growth inhibition of human HCT116 cells measured after 72 hrs by Celltiter-Glo assay Growth inhibition of human HCT116 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 32911078]
HeLa	GI₅₀	97.95 nM Compound: Torin2	Growth inhibition of human HeLa cells measured after 72 hrs by Celltiter-Glo assay Growth inhibition of human HeLa cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 32911078]
HeLa	IC₅₀	<10 nM Compound: 15	Inhibition of N-terminally FLAG-tagged mTORC2 (unknown origin) expressed in human HeLa cells using S6K1 or Akt1 as substrate after 20 mins by immunoblotting assay Inhibition of N-terminally FLAG-tagged mTORC2 (unknown origin) expressed in human HeLa cells using S6K1 or Akt1 as substrate after 20 mins by immunoblotting assay	[PMID: 29211480]
MOLM-13	IC₅₀	<1 nM Compound: Torin2	Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay	[PMID: 30370766]
MOLM-14	IC₅₀	<1 nM Compound: Torin2	Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay	[PMID: 30370766]
MV4-11	IC₅₀	<1 nM Compound: Torin2	Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay	[PMID: 30370766]
PC-3	EC₅₀	200 nM Compound: 3, Torin2	Inhibition of PI3Kalpha in human PC3 cells expressing Akt1 S473D mutant assessed as phosphorylation of Akt Thr308 by immunoblotting Inhibition of PI3Kalpha in human PC3 cells expressing Akt1 S473D mutant assessed as phosphorylation of Akt Thr308 by immunoblotting	[PMID: 21322566]
RD	CC₅₀	0.04 μM Compound: 1	Cytotoxicity against human RD cells incubated for 4 days by CellTiter-Glo luminescence assay Cytotoxicity against human RD cells incubated for 4 days by CellTiter-Glo luminescence assay	[PMID: 31082764]

In Vitro

Torin 2 is subject to further profiling against a panel of lipid kinases with IC₅₀s of 2.81 nM, 0.5 nM, 5.67 nM, 8.58 nM, 18.3 nM, 24.5 nM and 28.1 nM for mTOR, DNA-pK, p110γ, hVPS34, PI4Kβ, PI3K-C2β and PI3K-C2α, respectively. Torin 2 (Torin2) possesses a 250 pM EC₅₀ for inhibiting mTOR in cells while maintaining 800-fold cellular selectivity relative to inhibition of PI3K and most other protein kinases^[1]. Torin 2 (Torin2) exhibits potent biochemical and cellular activity against PIKK family kinases including ATM (EC₅₀ 28 nM), ATR (EC₅₀ 35 nM) and DNA-PK (EC₅₀ 118 nM). Torin 2 potently inhibits T308 of Akt, a direct substrate of PDK1 and an indirect substrate of PI3Ks, with an EC₅₀ of less than 10 nM^[2]. Torin-2 can suppress both mTORC1 and mTORC2^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Torin 2 exhibits good bioavailability and exposure and can maintain strong inhibition of mTOR activity in lung and liver to at least six hours after a single dose of 20 mg/kg. Torin 2 is easier to produce on scale and exhibits improved pharmacokinetic properties which should enable it use in vivo experiments^[1]. Torin 2 strongly suppresses pS6K(T389) and p4EBP1(T37/46) and partly suppresses pAkt(T308). Treatment of mice with AZD6244 at 25 mg/kg results in a profound inhibition of pERK. Combined administration of Torin 2 (40 mg/kg) and AZD6244 (25 mg/kg) demonstrates strong inhibition of all pharmacodynamics markers^[2]. Treatment with Torin 2 and Rapamycin induces IL-6 secretion by astrocytes and may contribute to the reduction of mechanical hypersensitivity after SCI. Torin1 and Torin 2 treatment increases IL-6 mRNA, suggesting that the PI3K-mTOR pathway is a negative regulator of IL-6 expression in astrocytes. Importantly, Torin 2 treatment does not show any cell toxicity, as no signs of cell death are observed by TUNEL assay or by detection of cleaved-caspase 3 by western blotting^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1223001-51-1
Appearance Solid
Masse moléculaire 432.40
Formule C₂₄H₁₅F₃N₄O
Color White to light yellow
SMILES

O=C1N(C2=C(C=C1)C=NC3=CC=C(C=C32)C4=CC=C(N=C4)N)C5=CC=CC(C(F)(F)F)=C5
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (21)

All WBBio/Physico-chemical AssayCell Imaging/StainingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nat Commun

A fast-acting lipid checkpoint in G1 prevents mitotic defects. [Abstract]

2024 Mar 18;15(1):2441. PMID: 38499565

Torin 2 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 18;15(1):2441. [Abstract]

MCF-10A cells were EGF released for indicated time points and treated with different inhibitors. Blotted for p-p70 S6 Kinase (T389), p70 S6 Kinase, and -actin. Inhibitor concentration used: C75 (15µM), Nutlin-3 (10µM), Torin2 (500nM).
J Clin Invest

Altered immune and metabolic molecular pathways drive islet cell dysfunction in human type 1 diabetes. [Abstract]

2025 Sep 30:e195267. PMID: 41026524

Torin 2 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2025 Sep 30:e195267. [Abstract]

Effects of mTOR inhibition by 1 μM Torin 2 on glucagon dynamic secretion perfusion in ND islets (4 donors). To mimic mTORC1 downregulation in T1D α cells and evaluate its effect on glucagon secretion, ND islets were treated with Torin 2 (mTOR inhibitor) and subjected to dynamic hormone secretion assays at 5 mM glucose. Increased glucagon secretion (and, to a lesser degree, insulin; data not shown) was observed following Torin 2 administration, indicating that diminished reduced mTORC1 signaling contributed to hypersecretion.
Cell Death Dis

Autophagic sequestration of SQSTM1 disrupts the aggresome formation of ubiquitinated proteins during proteasome inhibition. [Abstract]

2022 Jul 15;13(7):615. PMID: 35840557

Torin 2 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Jul 15;13(7):615. [Abstract]

AD293 cells were transfected with plasmids expressing mRFP-CFTR∆F508 for 24 h, and then treated with DMSO (control), or MG132 (2 μM), or MG132 (2 μM)/ Torin 2 (1 μM) for 14 h, or pretreated with Rapamycin (2 μM) for 10 h and then treated with MG132 (2 μM)/Rapamycin (2 μM) for 14 h. The aggresome formation of mRFP-CFTR∆F508 was analyzed by fluorescence microscope. Nuclei were stained with DAPI (blue). Scale bar: 20 μm. The results showed that Torin 2 strongly inhibited the aggresome formation of mRFP-CFTRΔF508 expressed in AD293 cells.
Cell Chem Biol

Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. [Abstract]

2020 Nov 19;27(11):1359-1370.e8. PMID: 32649904
Cell Syst

Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. [Abstract]

2020 Jan 22;10(1):66-81.e11. PMID: 31812693
Genes Dev

USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. [Abstract]

2021 Oct 1;35(19-20):1327-1332. PMID: 34531315
Sci Signal

Interleukins 15 and 18 synergistically prime the antitumor function of natural killer cells through noncanonical activation of mTORC1. [Abstract]

2025 Sep 16;18(904):eadq8778. PMID: 40956875
Mol Cancer Ther

mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells. [Abstract]

2018 Dec;17(12):2676-2688. PMID: 30282812

Torin 2 purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2018 Dec;17(12):2676-2688. [Abstract]

The mTORC1/2 inhibitor Torin 2 suppresses protein synthesis in the EW8 and TC71 Ewing sarcoma cell lines.
Plant J

The UPR regulator IRE1 promotes balanced organ development by restricting TOR-dependent control of cellular differentiation in Arabidopsis. [Abstract]

2022 Mar;109(5):1229-1248. PMID: 34902186
Front Pharmacol

CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. [Abstract]

2020 Nov 11;11:580407. PMID: 33343350
Molecules

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]

2020 Apr 23;25(8):1980. PMID: 32340370

Torin 2 purchased from MedChemExpress. Usage Cited in: Molecules. 2020 Apr 23;25(8):1980. [Abstract]

Torin 2 (15 mg/kg). Efficacy of tested compounds in L. donovani—infected BALB/c mice.
Parasite burden (LDU, Leishman-Donovan Unit) was evaluated 7 days after compound administration. Data are presented as mean ± SD; NA, not applicable.

Torin 2 purchased from MedChemExpress. Usage Cited in: Molecules. 2020 Apr 23;25(8):1980. [Abstract]

Mouse survival after treatment with 30 mg/kg pentamidine (solid green line), 15 mg/kg Torin 2 (solid black line) (p.o.; once daily), 5 mg/kg NVP-BGT226 (dotted black line), or the PBS control (solid blue line) for 5 days.
J Biol Chem

The E3 ligase β-TRCP1 earmarks OTUD3 for destruction to fine-tune cGAS activation. [Abstract]

2026 Jun;302(6):111461. PMID: 41999888
Lab Invest

Dectin-1 stimulates IL-33 expression in dendritic cells via upregulation of IRF4. [Abstract]

2018 Jun;98(6):708-714. PMID: 29540860
Naunyn Schmiedebergs Arch Pharmacol

Neural stem cell extracellular vesicle-mediated delivery of astragaloside IV attenuates hypoxic-ischemic brain damage by activating the mTOR pathway. [Abstract]

2026 May 16. PMID: 42142143
J Nat Prod

Clavukoellians A-F, Highly Rearranged Nardosinane Sesquiterpenoids with Antiangiogenic Activity from Clavularia koellikeri. [Abstract]

2019 May 24;82(5):1331-1337. PMID: 30994348
J Nat Prod

Salviachinensines A-F, Antiproliferative Phenolic Derivatives from the Chinese Medicinal Plant Salvia chinensis. [Abstract]

2018 Nov 26;81(11):2531-2538. PMID: 30370766
Biochem Biophys Res Commun

Schwann cell-specific PTEN and EGFR dysfunctions affect neuromuscular junction development by impairing Agrin signaling and autophagy. [Abstract]

2019 Jul 12;515(1):50-56. PMID: 31122699
bioRxiv

2026 Mar 25.
bioRxiv

2025 Sep 12.
Elife

Homeostasis of branched-chain amino acids is critical for the activity of TOR signaling in Arabidopsis. [Abstract]

2019 Dec 6;8:e50747. PMID: 31808741
Harvard Medical School LINCS LIBRARY

Solvant et solubilité

In Vitro:

DMSO : 15.62 mg/mL (36.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3127 mL

11.5634 mL

23.1267 mL

5 mM

0.4625 mL

2.3127 mL

4.6253 mL

10 mM

0.2313 mL

1.1563 mL

2.3127 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.56 mg/mL (3.61 mM); Clear solution

This protocol yields a clear solution of ≥ 1.56 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.6 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% 1-Methyl-2-pyrrolidinone 90% PEG300

Solubility: ≥ 2 mg/mL (4.63 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[2]

HCT116 cells are treated with 100 nM Torin 2 or AZD8055 for 1 hour before they are thoroughly washed out by 3×PBS and 1×DMEM medium. Then cells are incubated in DMEM medium for indicated time before they are lysed and collected using M-PER. Protein concentrations are measured and equal amount of proteins are loaded. Experiments are repeated three times and one set of results^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]^[3]

Mice^[1]
Six-week old male C57BL/6 mice are fasted overnight prior to Torin 2 treatment. The mice are treated with vehicle (for 10 h) or Torin 2 (20 mg/kg for 6h) via oral gavage and then re-fed 1 h prior to sacrifice (CO₂ asphyxiation). Liver and lung are collected and frozen on dry ice. The frozen tissue is thawed on ice and lysed by sonication in tissue lysis buffer (50 mM HEPES, pH 7.4, 40 mM NaCl, 2 mM EDTA, 1.5 mM sodium orthovanadate, 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 10 mM sodium β-glycerophosphate, 0.1% SDS, 1.0% sodium deoxycholate, and 1.0% Triton, supplemented with protease inhibitor cocktail tablets). The concentration of clear lysate is measured using the Bradford assay and samples are subsequently normalized by protein content and analyzed by SDS-PAGE and immunoblotting.
Rats^[3]
Female rats (220 g) are group-housed 4 animals per cage, and kept on a 12-hour light/dark cycle with food and water ad libitum. Spinal cord injury is done with the Keck Center for Neurosciences impactor using a 10 g weight dropped from a height of 25 mm onto the dorsal surface of the exposed spinal cord. After recording BBB scores, withdrawal thresholds evoked by touch stimulus, and body weights for the first week post-injury, animals are divided into 5 treatment groups: naïve (N=4), sham (N=6), vehicle (N=6), Torin 2 (N=6), and Torin 2+Rapamycin (N=8). Torin 2 alone (4 mg/kg) or in combination with Rapamycin (1.5 mg/kg) is administered orally by gavage once a day starting at day 15 after injury and ending at day 29. In sham operated rats only the laminectomy is performed.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Liu Q, et al. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem. 2011 Mar 10;54(5):1473-80. [Content Brief]

[2]. Liu Q, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 2013 Apr 15;73(8):2574-86. [Content Brief]

[3]. Codeluppi S, et al. Interleukin-6 secretion by astrocytes is dynamically regulated by PI3K-mTOR-calcium signaling. PLoS One. 2014 Mar 25;9(3):e92649. [Content Brief]

[4]. Wang X, et al. mTORC signaling in hematopoiesis. Int J Hematol. 2016 May;103(5):510-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3127 mL	11.5634 mL	23.1267 mL	57.8168 mL
	5 mM	0.4625 mL	2.3127 mL	4.6253 mL	11.5634 mL
	10 mM	0.2313 mL	1.1563 mL	2.3127 mL	5.7817 mL
	15 mM	0.1542 mL	0.7709 mL	1.5418 mL	3.8545 mL
	20 mM	0.1156 mL	0.5782 mL	1.1563 mL	2.8908 mL
	25 mM	0.0925 mL	0.4625 mL	0.9251 mL	2.3127 mL
	30 mM	0.0771 mL	0.3854 mL	0.7709 mL	1.9272 mL

Keywords

Torin 2

21 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Torin 2

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Torin 2

Voir tous les produits spécifiques à Isoform mTOR

Activité biologique

Chemical Information

Publications (21)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Torin 2 Related Classifications

HY-13002 Related Classifications